701 related articles for article (PubMed ID: 33021091)
21. Imaging-assisted anticancer nanotherapy.
Dasgupta A; Biancacci I; Kiessling F; Lammers T
Theranostics; 2020; 10(3):956-967. PubMed ID: 31938045
[TBL] [Abstract][Full Text] [Related]
22. The tumor EPR effect for cancer drug delivery: Current status, limitations, and alternatives.
Sun R; Xiang J; Zhou Q; Piao Y; Tang J; Shao S; Zhou Z; Bae YH; Shen Y
Adv Drug Deliv Rev; 2022 Dec; 191():114614. PubMed ID: 36347432
[TBL] [Abstract][Full Text] [Related]
23. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.
Shi Y; van der Meel R; Chen X; Lammers T
Theranostics; 2020; 10(17):7921-7924. PubMed ID: 32685029
[TBL] [Abstract][Full Text] [Related]
24. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
Maeda H
Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
[TBL] [Abstract][Full Text] [Related]
25. Tumor targeting via EPR: Strategies to enhance patient responses.
Golombek SK; May JN; Theek B; Appold L; Drude N; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2018 May; 130():17-38. PubMed ID: 30009886
[TBL] [Abstract][Full Text] [Related]
26. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
[TBL] [Abstract][Full Text] [Related]
28. Challenging the fundamental conjectures in nanoparticle drug delivery for chemotherapy treatment of solid cancers.
Yang J; Wang X; Wang B; Park K; Wooley K; Zhang S
Adv Drug Deliv Rev; 2022 Nov; 190():114525. PubMed ID: 36100142
[TBL] [Abstract][Full Text] [Related]
29. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
Khaitan D; Reddy PL; Ningaraj N
Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
[TBL] [Abstract][Full Text] [Related]
30. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
31. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
32. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers.
Fang J; Islam W; Maeda H
Adv Drug Deliv Rev; 2020; 157():142-160. PubMed ID: 32553783
[TBL] [Abstract][Full Text] [Related]
33. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: Designing a new perspective in nanomedicine delivery.
Dhaliwal A; Zheng G
Theranostics; 2019; 9(26):8091-8108. PubMed ID: 31754383
[TBL] [Abstract][Full Text] [Related]
34. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
[TBL] [Abstract][Full Text] [Related]
35. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
[TBL] [Abstract][Full Text] [Related]
36. Bypassing the EPR effect with a nanomedicine harboring a sustained-release function allows better tumor control.
Shen YA; Shyu IL; Lu M; He CL; Hsu YM; Liang HF; Liu CP; Liu RS; Shen BJ; Wei YH; Chuang CM
Int J Nanomedicine; 2015; 10():2485-502. PubMed ID: 25848266
[TBL] [Abstract][Full Text] [Related]
37. Anticancer nanomedicines harnessing tumor microenvironmental components.
Li Y; Chen Z; Gu L; Duan Z; Pan D; Xu Z; Gong Q; Li Y; Zhu H; Luo K
Expert Opin Drug Deliv; 2022 Apr; 19(4):337-354. PubMed ID: 35244503
[TBL] [Abstract][Full Text] [Related]
38. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
Nakamura H; Fang J; Maeda H
Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
[TBL] [Abstract][Full Text] [Related]
39. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
40. [The development of novel tumor targeting delivery strategy].
Gao HL; Jiang XG
Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]